Novogen - 22 Year Stock Price History | KZIA

Historical daily share price chart and data for Novogen since 1999 adjusted for splits. The latest closing stock price for Novogen as of September 24, 2021 is 11.21.
  • The all-time high Novogen stock closing price was 625.00 on December 05, 2003.
  • The Novogen 52-week high stock price is 15.85, which is 41.4% above the current share price.
  • The Novogen 52-week low stock price is 5.55, which is 50.5% below the current share price.
  • The average Novogen stock price for the last 52 weeks is 9.63.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Novogen Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2021 10.2524 8.9800 14.7100 8.6500 11.2100 29.75%
2020 5.1426 4.4900 13.4700 2.5600 8.6400 99.08%
2019 3.2396 2.4500 7.4000 2.2698 4.3400 78.60%
2018 3.9308 3.3500 6.2500 2.2026 2.4300 -23.58%
2017 4.0431 5.8400 7.1600 2.4000 3.1799 -45.74%
2016 7.8791 8.2000 11.0800 5.8400 5.8600 -29.90%
2015 14.2235 8.6400 36.9200 8.3600 8.3600 0.48%
2014 13.8010 17.2400 21.5200 6.5600 8.3200 -51.63%
2013 18.2647 27.8800 36.2000 7.3600 17.2000 -38.13%
2012 11.4127 11.0000 40.9600 6.0000 27.8000 247.50%
2011 17.2595 11.2000 43.4000 8.0000 8.0000 -21.57%
2010 24.2849 50.0000 58.4000 8.2000 10.2000 -79.27%
2009 49.7667 53.8000 98.6000 25.6000 49.2000 -1.20%
2008 105.1423 107.6000 174.0000 39.0000 49.8000 -54.64%
2007 178.3737 207.0000 252.0000 101.0000 109.8000 -45.96%
2006 242.6470 365.0000 368.2000 175.6000 203.2000 -44.08%
2005 387.7532 441.0000 454.0000 349.2000 363.4000 -17.71%
2004 409.8063 544.8000 588.0000 302.0000 441.6000 -19.12%
2003 319.2675 216.8000 625.0000 151.0000 546.0000 185.56%
2002 129.4881 150.0000 191.2000 64.6000 191.2000 18.76%
2001 120.5274 157.6000 228.8000 39.6000 161.0000 2.16%
2000 220.4802 200.0000 285.0000 157.6000 157.6000 -21.20%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.148B $0.001B
Kazia Therapeutics Limited is an oncology-focused biotechnology company. It develops anti-cancer drugs as well as provides pharmaceutical research and development technology solutions. The company's lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme, the primary and most aggressive form of brain cancer. Kazia Therapeutics Limited, formerly known as Novogen Limited, is based in Sydney, Australia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71